CL2009001125A1 - Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. - Google Patents

Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.

Info

Publication number
CL2009001125A1
CL2009001125A1 CL2009001125A CL2009001125A CL2009001125A1 CL 2009001125 A1 CL2009001125 A1 CL 2009001125A1 CL 2009001125 A CL2009001125 A CL 2009001125A CL 2009001125 A CL2009001125 A CL 2009001125A CL 2009001125 A1 CL2009001125 A1 CL 2009001125A1
Authority
CL
Chile
Prior art keywords
treatment
inflammatory diseases
compound
ach
cns
Prior art date
Application number
CL2009001125A
Other languages
English (en)
Inventor
Gregor James Macdonald
Johannes Wilhelmus John F Thuring
Wei Zhuang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39800623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2009001125A1 publication Critical patent/CL2009001125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

COMPUESTO DE FÓRMULA (1), O UN ESTEREOISÓMERO DEL MISMO, DONDE Z, Q, L, SON COMO SE<br /> DEFINE EN LAS REIVINDICACIONES, UNA SAL DE ADICIÓN ACEPTABLE DESDE EL PUNTO DE VISTA FARMACÉUTICO, O<br /> UN HIDRATO O UN SOLVATO DE LA MISMA.<br /> USO DE DICHO COMPUESTO PARA EL TRATAMIENTO O PROFILAXIS DE TRASTORNOS PSICÓTICOS, TRASTORNOS<br /> DEL DETERIORO INTELECTUAL O ENFERMEDADES INFLAMATORIAS.<br /> COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN PORTADOR ACEPTABLE DESDE EL PUNTO DE VISTA<br /> FARMACÉUTICO Y COMO INGREDIENTE ACTIVO UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE DICHO COMPUESTO.<br /> PROCESO PARA PREPARAR DICHA COMPOSICIÓN DONDE UN PORTADOR ACEPTABLE DESDE EL PUNTO DE<br /> VISTA FARMACÉUTICO SE MEZCLA ÍNTIMAMENTE CON UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE DICHO<br /> COMPUESTO.<br /> COMBINACIÓN FARMACÉUTICA QUE COMPRENDE: (A) DICHO COMPUESTO DE FÓRMULA (1), Y (B) UN<br /> AGONISTA DEL RECEPTOR NICOTÍNICO A7<br />  
CL2009001125A 2008-05-09 2009-05-08 Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. CL2009001125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08155991 2008-05-09

Publications (1)

Publication Number Publication Date
CL2009001125A1 true CL2009001125A1 (es) 2011-02-11

Family

ID=39800623

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001125A CL2009001125A1 (es) 2008-05-09 2009-05-08 Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.

Country Status (14)

Country Link
US (1) US8779158B2 (es)
EP (1) EP2280945B1 (es)
JP (1) JP5486591B2 (es)
KR (1) KR20110007234A (es)
CN (1) CN102015655A (es)
AR (1) AR071763A1 (es)
AU (1) AU2009245715B2 (es)
BR (1) BRPI0912196A2 (es)
CA (1) CA2722805A1 (es)
CL (1) CL2009001125A1 (es)
EA (1) EA018187B1 (es)
ES (1) ES2525132T3 (es)
TW (1) TWI440634B (es)
WO (1) WO2009135944A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
MX2010004177A (es) * 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv 1,2,4-triazoles trisustituidos.
CN102066343B (zh) * 2008-03-19 2013-12-04 詹森药业有限公司 作为烟碱乙酰胆碱受体调节剂的三取代1，2，4-三唑类
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
CA2770932C (en) 2009-09-17 2017-04-25 Janssen Pharmaceutica Nv Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
JP5865397B2 (ja) 2011-02-03 2016-02-17 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ α７ｎＡＣｈＲのモジュレータとして使用されるピロール誘導体
CN103402994B (zh) 2011-02-23 2017-05-31 鲁宾有限公司 作为α7 NACHR调节剂的杂芳基衍生物
MY161236A (en) 2011-02-25 2017-04-14 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
AU2012235779B2 (en) 2011-03-31 2017-03-02 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease
US8946432B2 (en) 2011-07-05 2015-02-03 Lupin Limited Biaryl derivatives as nAChR modulators
RU2616293C2 (ru) 2011-10-06 2017-04-14 Байер Интеллектуэль Проперти Гмбх Гетероциклилпиридинилпиразолы в качестве фунгицидного средства
IN2014MN01756A (es) 2012-03-06 2015-07-03 Lupin Ltd
WO2014072957A1 (en) 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
EP2970180A1 (en) 2013-03-13 2016-01-20 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
US9504680B2 (en) 2013-06-17 2016-11-29 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CN107652204A (zh) * 2017-09-30 2018-02-02 山东理工大学 一种环氧化物接枝肼还原制备及分散石墨烯的方法
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795907A (fr) 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
US3988348A (en) * 1975-03-14 1976-10-26 American Cyanamid Company 3, OR 5-Aminopyrazolium salts
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
GB8611102D0 (en) * 1986-05-07 1986-06-11 Fisons Plc Heterocyclic compounds
EP0248523B1 (en) 1986-05-07 1991-10-16 FISONS plc Pyrazoles
JPS6339868A (ja) 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
US4761422A (en) 1986-11-20 1988-08-02 Lusofarmaco Istituto Lusofarmaco D'italia Spa (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same
EP1125932A3 (en) 1994-07-27 2001-08-29 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
CA2276034A1 (en) 1996-12-23 1998-07-02 Mimi Lifen Quan Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2211420T3 (es) 1999-07-21 2004-07-16 F. Hoffmann-La Roche Ag Derivados de triazol.
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
AU3740101A (en) 2000-03-01 2001-09-12 Janssen Pharmaceutica Nv 2,4-disubstituted thiazolyl derivatives
AU2001249670A1 (en) 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2001296255B2 (en) 2000-09-21 2005-07-28 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
CN100357278C (zh) 2000-12-22 2007-12-26 奥索-麦克尼尔药品公司 作为激酶抑制剂的取代的三唑二胺衍生物
WO2003015773A2 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
JP2005510508A (ja) 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
WO2003062215A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
EP1506200B1 (en) 2002-05-07 2006-12-20 Neurosearch A/S Diazabicyclic biaryl derivatives
WO2004096225A2 (en) 2003-04-28 2004-11-11 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
ATE439837T1 (de) 2003-06-03 2009-09-15 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
WO2005012263A1 (en) 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2359007T3 (es) 2004-09-17 2011-05-17 Vertex Pharmaceuticals Incorporated Compuestos de diaminotriazol útiles como inhibidores de proteínas quinasas.
NZ555088A (en) 2004-10-21 2009-08-28 Vertex Pharma N-[(4-cyclohexyl)-phenyl]-[1,2,4]triazole-3,5-diamines useful as inhibitors of protein kinases
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
EP1926719B1 (en) 2005-09-13 2017-05-31 Janssen Pharmaceutica NV 2-aniline-4-aryl substituted thiazole derivatives
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
MX2010004177A (es) * 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv 1,2,4-triazoles trisustituidos.
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CN102066343B (zh) 2008-03-19 2013-12-04 詹森药业有限公司 作为烟碱乙酰胆碱受体调节剂的三取代1，2，4-三唑类
WO2009127678A1 (en) 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
CA2770932C (en) 2009-09-17 2017-04-25 Janssen Pharmaceutica Nv Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
JO3078B1 (ar) 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
MY161236A (en) 2011-02-25 2017-04-14 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr

Also Published As

Publication number Publication date
CN102015655A (zh) 2011-04-13
TW201006812A (en) 2010-02-16
ES2525132T3 (es) 2014-12-17
AU2009245715B2 (en) 2014-01-09
WO2009135944A1 (en) 2009-11-12
US8779158B2 (en) 2014-07-15
JP2011519901A (ja) 2011-07-14
AU2009245715A1 (en) 2009-11-12
US20110065683A1 (en) 2011-03-17
BRPI0912196A2 (pt) 2015-10-06
JP5486591B2 (ja) 2014-05-07
CA2722805A1 (en) 2009-11-12
EP2280945B1 (en) 2014-09-03
EA201071288A1 (ru) 2011-04-29
TWI440634B (zh) 2014-06-11
AR071763A1 (es) 2010-07-14
KR20110007234A (ko) 2011-01-21
EP2280945A1 (en) 2011-02-09
EA018187B1 (ru) 2013-06-28

Similar Documents

Publication Publication Date Title
CL2009001125A1 (es) Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
AR068919A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales.
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
EA201190142A1 (ru) Производные пиразола, используемые в качестве антагонистов рецептора ccr4
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
TN2013000257A1 (en) Immunosuppressant formulations
EA201270602A1 (ru) N-((1r,2s,5r)-5-(трет-бутиламино)-2-((s)-3-(7-трет-бутилпиразоло[1,5-а][1,3,5]триазин-4-иламино)-2-оксопирролидин-1-ил)циклогексил)ацетамид в качестве двойного модулятора активности хемокиновых рецепторов, его кристаллические формы и способы получения
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
TW200800984A (en) New compounds
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
AR108712A1 (es) (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis
EA200900244A1 (ru) Модуляторы активности хемокиновых рецепторов, их кристаллические формы и способ их получения
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
UA107702C2 (en) Novel benzamide derivatives
RS54420B1 (en) FORMULATION CONTAINING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE INGREDIENT
SV2011003896A (es) Pirrolidinas